Clinical Trials

16 enrolled

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

120 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

17 enrolled

Neoplasms, Central Nervous System Neoplasms

NCT04360941 2026-01-21

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

50 enrolled

Advanced Solid Tumor

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

21 enrolled

Carcinoma, Transitional Cell

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT04242238 2025-08-28

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

32 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT05222932 2025-08-07

AVENTIL

15 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

57 enrolled 56 charts

Tumor-Agnostic

Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03893903 2025-03-14

AMPLIFY-NEOVAC

69 enrolled

Glioma

NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

24 enrolled 25 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03845166 2024-11-19

STELLAR-001

GastrointestinalGenitourinary

325 enrolled

Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT02994953 2024-09-20

COMBO

52 enrolled 34 charts

Advanced Solid Tumors

NCT03200587 2024-07-03

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

12 enrolled

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03451825 2024-06-24

Phase I/II Study of Avelumab in Pediatric Cancer Participants

21 enrolled 21 charts

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03915405 2024-04-25

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

16 enrolled

Carcinoma, Transitional Cell

NCT03558139 2024-04-01

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

34 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT03523390 2024-02-23

Phase I/Ib Multiple Ascending Dose Study in China

24 enrolled 24 charts

Metastatic Solid Tumors

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

BreastGenitourinaryGynecologic

10 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

27 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastDermatologicGenitourinaryThoracic

12 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04601402 2023-08-08

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

GenitourinaryHead & NeckThoracic

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03267836 2023-06-15

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

9 enrolled

Meningioma

NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

8 enrolled 18 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03270176 2022-06-01

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

54 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

76 enrolled

Malignant Solid Tumour

NCT02493751 2022-02-18

JAVELIN Renal 100

55 enrolled 27 charts

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03341806 2022-01-04

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

13 enrolled

Glioblastoma

NCT02222922 2020-12-17

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

BreastGynecologicThoracic

138 enrolled 98 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03704467 2020-11-13

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer